EA201990213A1 - Композиции и способы, включающие усовершенствования гидовых рнк crispr с использованием промотора h1 - Google Patents

Композиции и способы, включающие усовершенствования гидовых рнк crispr с использованием промотора h1

Info

Publication number
EA201990213A1
EA201990213A1 EA201990213A EA201990213A EA201990213A1 EA 201990213 A1 EA201990213 A1 EA 201990213A1 EA 201990213 A EA201990213 A EA 201990213A EA 201990213 A EA201990213 A EA 201990213A EA 201990213 A1 EA201990213 A1 EA 201990213A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crispr
compositions
modifications
sequences
cas9
Prior art date
Application number
EA201990213A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of EA201990213A1 publication Critical patent/EA201990213A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к композициям и способам, включающим усовершенствование системы CRISPR (например, CRISPR-ассоциированная (Cas) 9 (системы CRISPR-Cas9, не Cas9 CRISPR)). Такие композиции могут содержать модификации промоторной области H1, добавление модификаций 5'UTR, различные ортологичные последовательности промотора H1, новые компактные последовательности двунаправленного промотора с активностью в отношении как pol II, так и pol III, вставку консенсусных последовательностей Козак, последовательностей терминации, вставку двунаправленного промотора pol II/pol III с зависимой от условий экспрессией, вставку донорной матричной последовательности для коррекции мутаций или их комбинации. Другие аспекты изобретения относятся к модификациям Cas9 посредством слитых конструкций для посттрансляционной регуляции клеточного цикла, сконструированных частичных участков-мишеней, чтобы нуклеаза могла связываться без расщепления, участков ауторегуляции и N-концевых модификаций для модулирования времени полужизни.
EA201990213A 2016-07-05 2017-07-05 Композиции и способы, включающие усовершенствования гидовых рнк crispr с использованием промотора h1 EA201990213A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662358335P 2016-07-05 2016-07-05
PCT/US2017/040707 WO2018009534A1 (en) 2016-07-05 2017-07-05 Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter

Publications (1)

Publication Number Publication Date
EA201990213A1 true EA201990213A1 (ru) 2019-11-29

Family

ID=60912275

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990213A EA201990213A1 (ru) 2016-07-05 2017-07-05 Композиции и способы, включающие усовершенствования гидовых рнк crispr с использованием промотора h1

Country Status (14)

Country Link
US (1) US11766488B2 (ru)
EP (1) EP3481956A4 (ru)
JP (2) JP2019520078A (ru)
KR (1) KR20190039702A (ru)
CN (1) CN109844116A (ru)
AU (2) AU2017292667A1 (ru)
BR (1) BR112019000055A2 (ru)
CA (1) CA3029860A1 (ru)
CL (1) CL2019000025A1 (ru)
EA (1) EA201990213A1 (ru)
IL (1) IL264020A (ru)
MX (1) MX2019000251A (ru)
SG (1) SG11201900038QA (ru)
WO (1) WO2018009534A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3688159A4 (en) * 2017-09-26 2021-10-20 The Board of Trustees of the University of Illinois CRISPR / CAS SYSTEM AND PROCESS FOR GENOME EDITING AND TRANSCRIPT MODULATION
WO2019102381A1 (en) 2017-11-21 2019-05-31 Casebia Therapeutics Llp Materials and methods for treatment of autosomal dominant retinitis pigmentosa
CN108728441B (zh) * 2018-04-18 2022-07-22 深圳市第二人民医院 特异性识别p53突变的基因系统
CN112654710A (zh) 2018-05-16 2021-04-13 辛瑟高公司 用于指导rna设计和使用的方法和系统
EP3805394A4 (en) * 2018-05-25 2022-03-09 University of Tsukuba METHOD OF PRODUCTION OF FUSION PROTEIN, NUCLEIC ACID, CELL AND ANIMAL
WO2020059708A1 (ja) * 2018-09-17 2020-03-26 国立大学法人東京医科歯科大学 Ｃａｓタンパク質の活性調節法
DE112019005166T5 (de) * 2018-10-16 2021-07-29 Blueallele, Llc Verfahren zur gezielten insertion von dna in gene
AU2019370297A1 (en) * 2018-11-01 2021-05-27 Blueallele Corporation Methods for altering gene expression for genetic disorders
CN113272436B (zh) * 2018-11-08 2024-08-23 国立大学法人东海国立大学机构 使用利用单一的aav载体的基因组编辑的基因治疗
WO2020264254A1 (en) * 2019-06-28 2020-12-30 Crispr Therapeutics Ag Materials and methods for controlling gene editing
KR20220031070A (ko) * 2019-07-08 2022-03-11 인스크립타 인코포레이티드 Lexa-rad51 융합 단백질을 통한 증가된 핵산-가이드된 세포 편집
CN110622921B (zh) * 2019-09-29 2021-06-15 江苏大学 阿尔茨海默病病变区FoxG1过表达小鼠模型的构建方法及应用
CN110607302A (zh) * 2019-10-09 2019-12-24 广州医科大学附属第二医院 检测花生四烯酸脂氧合酶aloxe3基因启动子突变的方法及其应用
CN111718933B (zh) * 2020-06-28 2022-01-28 暨南大学 一种rrbp1基因敲除热带爪蛙模型的制备方法与应用
WO2022212768A2 (en) * 2021-03-31 2022-10-06 Hunterian Medicine Llc Compact promoters for gene editing
JPWO2023120536A1 (ru) * 2021-12-21 2023-06-29
WO2024050547A2 (en) * 2022-09-02 2024-03-07 Hunterian Medicine Llc Compact bidirectional promoters for gene expression

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4198626A (en) 1977-09-02 1980-04-15 Rauscher Frank J Intravenous alarm device
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4931777A (en) 1988-11-16 1990-06-05 Chiang Cheng San Low level alarm for drop-feed injection liquid
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5112319A (en) 1991-05-14 1992-05-12 Eric Lai Infusion alarm system
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US6121555A (en) 1997-10-10 2000-09-19 Northgate Technologies Incorporated Fluid container sensor
US7750817B2 (en) 1999-12-10 2010-07-06 Beverage Metrics Holding Ltd System and method using a scale for monitoring the dispensing of a beverage
JP2001343294A (ja) 2000-05-31 2001-12-14 Ishida Co Ltd ロードセル及び秤
GB0130955D0 (en) 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
US7180015B2 (en) 2004-09-24 2007-02-20 Hudson Douglas A Scale with clampable protrusion for weighing bicycles and other sports-related items
US10022457B2 (en) 2005-08-05 2018-07-17 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
US20070106177A1 (en) 2005-10-11 2007-05-10 Yoshito Hama Apparatus for collecting and calculating quantity of patient fluid loss and method of using same
US20080293142A1 (en) * 2007-04-19 2008-11-27 The Board Of Regents For Oklahoma State University Multiple shRNA Expression Vectors and Methods of Construction
KR101196701B1 (ko) 2009-07-16 2012-11-07 주식회사 실티 가축용 자동 급수장치
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
WO2012166662A1 (en) 2011-05-27 2012-12-06 Pet Wireless, Llc Systems, methods and computer program products for monitoring the behavior, health, and/or characteristics of an animal
US10704060B2 (en) * 2013-06-05 2020-07-07 Duke University RNA-guided gene editing and gene regulation
US20150251894A1 (en) 2014-03-06 2015-09-10 Julie Barbara Lake Transportable Device for Automatically Filling Water Buckets, Troughs and Containers
US9938521B2 (en) * 2014-03-10 2018-04-10 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
CA2943622A1 (en) 2014-03-25 2015-10-01 Editas Medicine Inc. Crispr/cas-related methods and compositions for treating hiv infection and aids
AU2015277369B2 (en) * 2014-06-16 2021-08-19 The Johns Hopkins University Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter
EP2982758A1 (en) * 2014-08-04 2016-02-10 Centre Hospitalier Universitaire Vaudois (CHUV) Genome editing for the treatment of huntington's disease
WO2016054225A1 (en) * 2014-09-30 2016-04-07 Stc.Unm Plasmid delivery in the treatment of cancer and other disease states
AU2015330699B2 (en) * 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
ES2983094T3 (es) 2014-10-31 2024-10-21 Univ Pennsylvania Alteración de la expresión génica en células CAR-T y usos de los mismos
US11680268B2 (en) 2014-11-07 2023-06-20 Editas Medicine, Inc. Methods for improving CRISPR/Cas-mediated genome-editing
CN104531632A (zh) * 2014-11-18 2015-04-22 李云英 快速降解的Cas9-ODC422-461融合蛋白及其应用
CA2970370A1 (en) * 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
CN204440762U (zh) 2015-02-09 2015-07-01 刘苹芳 阿基米德原理演示仪
JP2018518969A (ja) 2015-06-24 2018-07-19 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ．， ＬＬＣ 細胞周期依存性のゲノムの調節及び修飾
GB2541459B (en) 2015-08-21 2021-01-13 Carton Bernard A method and system for monitoring pregnancy toxaemia

Also Published As

Publication number Publication date
JP2022153576A (ja) 2022-10-12
SG11201900038QA (en) 2019-02-27
EP3481956A1 (en) 2019-05-15
AU2017292667A1 (en) 2019-02-21
US20190314521A1 (en) 2019-10-17
CL2019000025A1 (es) 2019-06-21
WO2018009534A1 (en) 2018-01-11
US11766488B2 (en) 2023-09-26
IL264020A (en) 2019-02-03
MX2019000251A (es) 2019-10-09
JP2019520078A (ja) 2019-07-18
BR112019000055A2 (pt) 2019-04-02
AU2023266246A1 (en) 2023-12-07
EP3481956A4 (en) 2020-07-08
KR20190039702A (ko) 2019-04-15
CN109844116A (zh) 2019-06-04
CA3029860A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
EA201990213A1 (ru) Композиции и способы, включающие усовершенствования гидовых рнк crispr с использованием промотора h1
PH12021550843A1 (en) Nucleic acid constructs and methods of use
WO2020123887A3 (en) Novel crispr-cas systems for genome editing
MX2020004578A (es) Composiciones de casz y metodos de uso.
GB2573062A (en) AAV delivery of nucleobase editors
BR112020024863A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
NZ763572A (en) Trispecific proteins and methods of use
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
EP4275698A3 (en) Anti-tigit antibodies and methods of use thereof
MX2019003674A (es) Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas.
MX2018013784A (es) Proteinas de fusion gdf15 y usos de estas.
MX2022004786A (es) Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular.
EA201991849A1 (ru) Система и способ редактирования генома
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
SG10201805815YA (en) Rna-guided gene drives
ZA202002325B (en) Constrained conditionally activated binding proteins
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
NZ742040A (en) Engineered nucleic-acid targeting nucleic acids
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
BR112016029178A2 (pt) composições e métodos para a expressão de rnas guia de crispr usando o promotor h1
BR112015023489A2 (pt) uso de rnas-guia truncads (tru - grnas) para aumentar a especificidade de edição de genoma com rna guiado
WO2017222619A3 (en) SEQUENCE ARRANGEMENTS AND SEQUENCES FOR THE PRESENTATION OF NEO-EPOPOPES
MX2017002900A (es) Terapia genica de globina para el tratamiento de hemoglobinopatias.
MX2022002315A (es) Anticuerpos anti-cd96 y sus metodos de uso.
PH12021550256A1 (en) Novel crispr-associated protein and use thereof